Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
Vaxcyte, Inc. (PCVX), a Delaware corporation, filed this Current Report on Form 8-K on August 5, 2026. The filing announces the company's financial results for the quarter ended June 30, 2026. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing explicitly states that the financial details are incorporated by reference from the press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as the specific financial figures required for comparison are absent.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other registration statements unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the quarter ended June 30, 2026, as they are not listed in the 8-K body text.
- Check for any forward-looking statements or updated clinical trial milestones in the referenced press release.
- Confirm the company's cash runway and burn rate from the full financial disclosure.